David Mackie

Dr. David Mackie


Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2012 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
YBYara Backes
Yara Backes
KSKoenraad F. van der Sluijs
Koenraad F. van der Sluijs
DMDavid Mackie
David Mackie
FTFrank Tacke
Frank Tacke
AKAlexander Koch
Alexander Koch
MSMarcus J. Schultz
Marcus J. Schultz
Purpose Systemic levels of soluble urokinase-type plasminogen activator receptor (suPAR) positively correlate with the activation level of the immune system. We reviewed the usefulness of systemic levels of suPAR in the care of critically ill patients with sepsis, SIRS, and bacteremia, focusing on its diagnostic and prognostic value. Methods A PubMed search on suPAR was conducted, including manual cross-referencing. The list of papers was narrowed to original studies of critically ill patients. Ten papers on original studies of critically ill patients were identified that report on suPAR in sepsis, SIRS, or bacteremia. Results Systematic levels of suPAR have little diagnostic value in critically ill patients with sepsis, SIRS, or bacteremia. Systemic levels of suPAR, however, have superior prognostic power over other commonly used biological markers in these patients. Mortality prediction by other biological markers or severity-of-disease classification system scores improves when combining them with suPAR. Systemic levels of suPAR correlate positively with markers of organ dysfunction and severity-of-disease classification system scores. Finally, systemic levels of suPAR remain elevated for prolonged periods after admission and only tend to decline after several weeks. Notably, the type of assay used to measure suPAR as well as the age of the patients and underlying disease affect systemic levels of suPAR. Conclusions The diagnostic value of suPAR is low in patients with sepsis. Systemic levels of suPAR have prognostic value, and may add to prognostication of patients with sepsis or SIRS complementing severity-of-disease classification systems and other biological markers.

1 April 1993 in Burns
Verified
Journal Article
Closed access
RKR.W. Kreis
R.W. Kreis
DMDavid Mackie
David Mackie
AVA.W.F.P. Vloemans
A.W.F.P. Vloemans
RHR.P. Hermans
R.P. Hermans
MHM.J. Hoekstra
M.J. Hoekstra

1 January 1991 in Anaesthesia
Verified
Journal Article
Closed access
PDF file
JGJ. B. M. Guit
J. B. M. Guit
HKH. M. Koning
H. M. Koning
MCM. L. Coster
M. L. Coster
RNR. P. E. Niemeijer
R. P. E. Niemeijer
DMDavid Mackie
David Mackie

1 January 1989
Verified
Journal Article
Closed access
RKR. W. Kreis
R. W. Kreis
AVA. F. P. M. Vloemans
A. F. P. M. Vloemans
MHM. J. Hoekstra
M. J. Hoekstra
DMDavid Mackie
David Mackie
RHR. P. Hermans
R. P. Hermans
Allograft skin lyophilised in 98% glycerol is an effective overlay for widely expanded autografts. The technique was evaluated clinically on a total of 58 sandwich grafting procedures in a group of 39 patients with extensive third-degree burns. Forty-five grafting operations performed within 10 days postburn all resulted in an epithelialisation rate of at least 75% within 5 weeks. Thirty-three of these procedures achieved complete (more than 95%) wound closure. Of 13 operations performed after the 14th postburn day, ten resulted in a wound epithelialisation of at least 75%. Epithelial quality and cosmetic results were good. The mean length of hospitalisation was 56 days. One patient died from unassociated respiratory failure. The absence of allograft viability did not impair its function as an autograft overlay. The apparent attenuation of allograft antigenicity conferred by the action of 98% glycerol may have contributed to the results achieved. The process of cadaver skin preservation in 98% glycerol is simple and inexpensive.

1 January 1994 in Burns
Verified
Journal Article
Closed access
RKR.W. Kreis
R.W. Kreis
DMDavid Mackie
David Mackie
RHR.P. Hermans
R.P. Hermans
AVA.R. Vloemans
A.R. Vloemans

1 December 1999 in Burns
Verified
Journal Article
Closed access
PZPaul van Zuijlen
Paul van Zuijlen
RKR.W. Kreis
R.W. Kreis
AVA.F.P.M. Vloemans
A.F.P.M. Vloemans
FGF. Groenevelt
F. Groenevelt
DMDavid Mackie
David Mackie